Brief: Inflarx NV Receives European Approval To Initiate Phase II Clinical Trial With IFX-1
19/12/2018 14:41
Dec 19 (Reuters) - Inflarx NV IFRX.O :
* INFLARX RECEIVES EUROPEAN APPROVAL TO INITIATE PHASE II
CLINICAL
TRIAL WITH IFX-1 IN ANCA-ASSOCIATED VASCULITIS
* INFLARX NV - STUDY IS EXPECTED TO INITIATE IN Q1 OF 2019.
Source text for Eikon: ID:nGNX6s9Dxp
Further company coverage: IFRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Inflarx NV
See all newsBrief: Inflarx NV Files For Offerng Of Ordinary Shares, Size Not Disclosed - SEC Filing
Brief: InflaRx Reports Full Year 2025 Results And Highlights Key Achievements And Expected Milestones
Brief: Inflarx Announces Late-Breaker Oral Presentation On Vilobelimab Phase 3 Results In Pyoderma Gangrenosum At 2026 American Academy Of Dermatology Annual Meeting
Brief: Inflarx NV Executing 30% Workforce Reduction
Brief: Inflarx Provides Update On Phase 3 Data Analyses For Vilobelimab In Pyoderma Gangrenosum